Thomas Steyer’s Solid Biosciences SLDB Stock Holding History

Thomas Steyer’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19,667	Closed	-$13.9M	–	102
2018 Q3	$13.9M	Buy	+19,667	New	+$12.4M	0.08%	78

Other funds holding SLDB

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's SLDB Position: Q4 2018 in Review

Thomas Steyer sold out of Solid Biosciences (SLDB) in Q4 2018, closing a stake of 19,667 shares — an estimated $13.9M sold.

Thomas Steyer first reported a position in SLDB in Q3 2018 and held it in 1 quarter. The position peaked at $13.9M in Q3 2018. 75 funds tracked by Wall St. Rank hold SLDB as of Q4 2018.

Thomas Steyer reported no remaining Solid Biosciences position as of Q4 2018 after selling out during the quarter.
Thomas Steyer sold 19,667 Solid Biosciences shares in Q4 2018, an estimated $13.9M.
Thomas Steyer first reported a position in Solid Biosciences in Q3 2018 and held it in 1 quarter.
Thomas Steyer's Solid Biosciences position peaked at $13.9M in Q3 2018.
75 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2018.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.